Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe

被引：28
|
作者：
Reinert, Ralf R. [1 ]
Paradiso, Peter [2 ]
Fritzell, Bernard [1 ]
机构：
[1] Pfizer Inc, Int Sci & Clin Affairs Vaccines, Paris, France
[2] Pfizer Inc, Collegeville, PA USA
来源：
EXPERT REVIEW OF VACCINES | 2010年 / 9卷 / 03期
关键词：
PNEUMONIAE SEROTYPE 19A; ACUTE OTITIS-MEDIA; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; CHILDHOOD IMMUNIZATION; IMPACT; CHILDREN; DISEASE; POLYMORPHISMS; RESISTANCE;
D O I：
10.1586/ERV.10.6
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：229 / 236
页数：8
相关论文
共 50 条
  • [31] Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study
    Ricketson, Leah J.
    Bettinger, Julie A.
    Sadarangani, Manish
    Halperin, Scott A.
    Kellner, James D.
    VACCINE, 2022, 40 (19) : 2733 - 2740
  • [32] ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE WITHIN THE PRIVATE MARKET IN BRAZIL
    Souza, C. P. R.
    Moraes, J. C.
    Berezin, E.
    Monteiro, R.
    Presa, J.
    Almeida, G.
    VALUE IN HEALTH, 2010, 13 (03) : A190 - A190
  • [33] Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia
    Urbancikova, Ingrid
    Prymula, Roman
    Goldblatt, David
    Roalfe, Lucy
    Prymulova, Karolina
    Kosina, Pavel
    VACCINE, 2017, 35 (38) : 5186 - 5193
  • [34] Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines
    Chuck, Anderson W.
    Jacobs, Philip
    Tyrrell, Gregory
    Kellner, James D.
    VACCINE, 2010, 28 (33) : 5485 - 5490
  • [35] Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-nave indigenous population
    Verhagen, Lilly M.
    Rivera-Oliverol, Ismar A.
    Hermsen, Meyke
    Sisco, Maria Carolina
    Maes, Mailis
    del Nogal, Berenice
    Bogaert, Debby
    Berbers, Guy A. M.
    Hermans, Peter W. M.
    de Jonge, Marien I.
    de Waard, Jacobus H.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (05) : 1492 - 1496
  • [36] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease Reply
    Naucler, Pontus
    Galanis, Ilias
    Morfeldt, Eva
    Darenberg, Jessica
    Ortqvist, Ake
    Henriques-Normark, Birgitta
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1642 - 1643
  • [37] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan
    Huang, Li-Min
    Lin, Tzou-Yien
    Juergens, Christine
    VACCINE, 2012, 30 (12) : 2054 - 2059
  • [38] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Jansen, Kathrin U.
    Jayawardene, Deepthi
    Devlin, Carmel
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3577 - 3584
  • [39] The Antibody Response Following a Booster With Either a 10-or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy
    Truck, Johannes
    Jawad, Sena
    Goldblatt, David
    Roalfe, Lucy
    Snape, Matthew D.
    Voysey, Merryn
    Pollard, Andrew J.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (07) : 787 - 793
  • [40] Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
    Turner, Paul
    Turner, Claudia
    Suy, Kuong
    Soeng, Sona
    Ly, Sokeng
    Miliya, Thyl
    Goldblatt, David
    Day, Nicholas P. J.
    EMERGING INFECTIOUS DISEASES, 2015, 21 (11) : 2080 - 2083
12345